Fer Gene
Biotechnology, 245 Main St, Cambridge, , 2142, Massachusetts, United States, 11-50 Employees
Phone Number: +16*********
Who is FERGENE
FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC). Our goal is...
Read More
-
Headquarters: 245 Main St, Cambridge, Massachusetts, 2142, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
FerGene Org Chart and Mapping
Email
Phone
Similar Companies to FerGene
64x Bio
-
11-50
-
$ 5 Million to 10 Million
Be Biopharma
-
11-50
-
$ 1 Million to 5 Million
CG Oncology
-
11-50
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding FerGene
Answer: FerGene's headquarters are located at 245 Main St, Cambridge, , 2142, Massachusetts, United States
Answer: FerGene's phone number is +16*********
Answer: FerGene's official website is https://fergene.com
Answer: FerGene's revenue is $100 Million to $250 Million
Answer: FerGene's SIC: 2836
Answer: FerGene's NAICS: 325414
Answer: FerGene has 11-50 employees
Answer: FerGene is in Biotechnology
Answer: FerGene top competitors include: 64x Bio , Be Biopharma , CG Oncology
Answer: FerGene contact info: Phone number: +16********* Website: https://fergene.com
Answer: FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC). Our goal is to provide greater hope to patients with this disease, who have seen little improvement in their standard of care over the past 20 years. FerGene, Inc. is a privately held company, created through a joint partnership between Ferring Pharmaceuticals and Blackstone Life Sciences. With over $570 million in funding, FerGene is preparing to commercialize nadofaragene firadenovec (rAd-IFN/Syn3) for high-grade, BCG-unresponsive NMIBC for the US market. Phase 3 data for nadofaragene firadenovec were presented at the Society of Urologic Oncology Congress in December 2019.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month